Literature DB >> 12871083

Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology.

Martin Weinmann1, Stefan Welz, Michael Bamberg.   

Abstract

Tumor hypoxia is a major constraint for the tumor treatment by radiotherapy. The efficacy of ionizing radiation directly relies on adequate oxygen tensions. Furthermore, hypoxia is related to malignant progression, increased invasion, angiogenesis and an increased risk of metastases formation. Two different types of strategies can be used to overcome the problem of hypoxia-mediated radioresistance. The first strategy encompasses a variety of different methods to improve the tumor oxygenation during radiotherapy. The second strategy tries to target hypoxia as a relatively unique feature of tumor tissue by means of drugs, which are activated under hypoxic conditions and act as hypoxic radiosensitizers or hypoxic cytotoxins. This article reviews in brief the clinical experience with different generations of hypoxic radiosensitizers and hypoxic cytotoxins, which have been applied in combination with primary radiotherapy during the last three decades.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871083     DOI: 10.2174/1568011033482350

Source DB:  PubMed          Journal:  Curr Med Chem Anticancer Agents        ISSN: 1568-0118


  5 in total

1.  Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.

Authors:  Nilesh K Wagh; Zhengyuan Zhou; Sunny M Ogbomo; Wen Shi; Susan K Brusnahan; Jered C Garrison
Journal:  Bioconjug Chem       Date:  2012-02-16       Impact factor: 4.774

2.  Sodwanone and yardenone triterpenes from a South African species of the marine sponge Axinella inhibit hypoxia-inducible factor-1 (HIF-1) activation in both breast and prostate tumor cells.

Authors:  Jingqiu Dai; James A Fishback; Yu-Dong Zhou; Dale G Nagle
Journal:  J Nat Prod       Date:  2006-12       Impact factor: 4.050

3.  Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells.

Authors:  Wafica Itani; Fady Geara; Joelle Haykal; Makhluf Haddadin; Hala Gali-Muhtasib
Journal:  Radiat Oncol       Date:  2007-01-03       Impact factor: 3.481

4.  The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.

Authors:  Hironobu Yasui; Taketoshi Asanuma; Junichi Kino; Tohru Yamamori; Shunsuke Meike; Masaki Nagane; Nobuo Kubota; Mikinori Kuwabara; Osamu Inanami
Journal:  BMC Cancer       Date:  2013-03-08       Impact factor: 4.430

5.  Electron Ionization of Imidazole and Its Derivative 2-Nitroimidazole.

Authors:  Rebecca Meißner; Linda Feketeová; Anita Ribar; Katharina Fink; Paulo Limão-Vieira; Stephan Denifl
Journal:  J Am Soc Mass Spectrom       Date:  2019-10-30       Impact factor: 3.109

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.